Stockscreener 앱 받기
0.9119
10.51%
0.0867
시장 영업 전:
.97
0.0581
+6.37%
Context Therapeutics Inc 주식(CNTX)의 최신 뉴스
What risks could impact 374Water Inc. stock performanceReal Time Stock Signal - Newser
How Bio Techne Corporation stock performs during market volatilityFree Expert-Led Investment Training - Newser
Why Context Therapeutics Inc. stock attracts strong analyst attentionShort Term High Return Strategy - Newser
How Context Therapeutics Inc. stock performs during market volatilityBig Return Stock Tips - Newser
Why VTGN stock attracts strong analyst attentionFree Stock Investment Growth Plan - Newser
Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms | DelveInsight - GlobeNewswire
What makes HighPeak Energy Inc. stock price move sharplyBest Stocks for Capital Safety - Newser
What makes Five Point Holdings LLC stock price move sharplyFree High-Profit Stock Picks - Newser
What makes Humana Inc. stock price move sharplyFree Trading Strategy Suggestions - Newser
What makes Context Therapeutics Inc. stock price move sharplyAlpha Stock Ideas - Newser
What makes Heritage Insurance Holdings Inc. stock price move sharplyFree Stock Market Courses - Newser
How Seneca Foods Corporation stock performs during market volatilityFree Investment Risk Control - Newser
How BlackSky Technology Inc. stock performs during market volatilityTargeted 200 Percent Gain - Newser
What makes EastGroup Properties Inc. stock price move sharplyFree Access to Stock Community - Newser
Why AREC stock attracts strong analyst attentionFree Stock Movement Tracking - Newser
Unpacking Q1 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) In The Context Of Other Therapeutics Stocks - Yahoo Finance
Rare Stock Picks In June 2025From 26 Discerning Analysts - Seeking Alpha
Piper Sandler Remains a Buy on Context Therapeutics (CNTX) - The Globe and Mail
Brokerages Set Context Therapeutics Inc. (NASDAQ:CNTX) Price Target at $6.00 - Defense World
Dominari (NASDAQ:DOMH) and Context Therapeutics (NASDAQ:CNTX) Critical Comparison - Defense World
Piper Sandler Adjusts Price Target for Context Therapeutics (CNT - GuruFocus
In a Context of Critical Financial Situation, CARMAT Launches a Donation Campaign Open to All to Contribute to Its Funding and Continuation of Its Activities - Yahoo Finance
Citadel Advisors LLC Makes New $31,000 Investment in Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
Millennium Management LLC Purchases 34,835 Shares of Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
Millennium Management LLC Has $191,000 Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
Context Therapeutics Approves Reverse Stock Split Amendment - TipRanks
Context Therapeutics Inc (CNTX) Stock: From Low to High in 52 Weeks - investchronicle.com
Context Therapeutics Names Dr. Karen Chagin as Chief Medical Officer - MSN
Co-Founder of Context Therapeutics Martin Lehr Buys 10% More Shares - simplywall.st
Insider Spends US$70k Buying More Shares In Context Therapeutics - 富途牛牛
Context Therapeutics Executives Increase Holdings - TradingView
Context Therapeutics: Undervalued Cancer Fighter (NASDAQ:CNTX) - Seeking Alpha
Jane Street Group LLC Makes New $29,000 Investment in Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
ContextLogic's OTC Gamble: Can a $6 Floor Launch a $15 Comeback? - AInvest
CNTXContext Therapeutics Reports First Quarter 2025 Operating and Financial Results - mx.advfn.com
Northern Trust Corp Sells 58,946 Shares of Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
Context Therapeutics Inc. Advances CTIM-76 in Phase 1 Trial for Solid Tumors with Initial Data Expected in 2026 - Nasdaq
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting - GlobeNewswire
Context Therapeutics' Cancer Drug CTIM-76 Progresses in Phase 1 Trial: Key Updates from ASCO 2025 - Stock Titan
Context Therapeutics names new CMO to advance T cell therapies By Investing.com - Investing.com South Africa
Context Therapeutics (CNTX) Names New Chief Medical Officer | CN - GuruFocus
Context Therapeutics (CNTX) Names New Chief Medical Officer | CNTX Stock News - GuruFocus
Context Therapeutics names new CMO to advance T cell therapies - Investing.com
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer - GlobeNewswire
Context Therapeutics Appoints Developer of First FDA-Approved Solid Tumor Cell Therapy as Chief Medical Officer - Stock Titan
Surging Prevalence Of Breast Cancer Fuels Expansion In The Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drug... - WhaTech
Context Therapeutics Grants Stock Options to New Hires as Part of Strategic Talent Growth - MSN
Context Therapeutics Names Dr. Karen Smith as Interim Chief Medical Officer - MSN
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.40 Consensus Price Target from Analysts - Defense World
Context Therapeutics Reports Q1 2025 Financial Results and Clinical Progress - MSN
Unpacking Q1 Earnings: Privia Health (NASDAQ:PRVA) In The Context Of Other Healthcare Technology for Providers Stocks - Yahoo Finance
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
0.64%
0.37%
자본화:
|
볼륨(24시간):